A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies

• Main Authors: Ruud G. Nijman, Rianne Oostenbrink, Henriette A. Moll, Climent Casals-Pascual, Ulrich von Both, Aubrey Cunnington, Tisham De, Irini Eleftheriou, Marieke Emonts, Colin Fink, Michiel van der Flier, Ronald de Groot, Myrsini Kaforou, Benno Kohlmaier, Taco W. Kuijpers, Emma Lim, Ian K. Maconochie, Stephane Paulus, Federico Martinon-Torres, Marko Pokorn, Sam T. Romaine, Irene Rivero Calle, Luregn J. Schlapbach, Frank J. Smit, Maria Tsolia, Effua Usuf, Victoria J. Wright, Shunmay Yeung, Dace Zavadska, Werner Zenz, Michael Levin, Jethro A. Herberg, Enitan D. Carrol, The PERFORM consortium (Personalized Risk assessment in febrile children to optimize Real-life Management across the European Union)
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-07-01
• Series: Frontiers in Pediatrics
• Subjects: serious bacterial infection; children; biomarkers; sepsis; clinical phenotypes
• Online Access: https://www.frontiersin.org/articles/10.3389/fped.2021.688272/full

Background: The limited diagnostic accuracy of biomarkers in children at risk of a serious bacterial infection (SBI) might be due to the imperfect reference standard of SBI. We aimed to evaluate the diagnostic performance of a new classification algorithm for biomarker discovery in children at risk of SBI.Methods: We used data from five previously published, prospective observational biomarker discovery studies, which included patients aged 0– <16 years: the Alder Hey emergency department (n = 1,120), Alder Hey pediatric intensive care unit (n = 355), Erasmus emergency department (n = 1,993), Maasstad emergency department (n = 714) and St. Mary's hospital (n = 200) cohorts. Biomarkers including procalcitonin (PCT) (4 cohorts), neutrophil gelatinase-associated lipocalin-2 (NGAL) (3 cohorts) and resistin (2 cohorts) were compared for their ability to classify patients according to current standards (dichotomous classification of SBI vs. non-SBI), vs. a proposed PERFORM classification algorithm that assign patients to one of eleven categories. These categories were based on clinical phenotype, test outcomes and C-reactive protein level and accounted for the uncertainty of final diagnosis in many febrile children. The success of the biomarkers was measured by the Area under the receiver operating Curves (AUCs) when they were used individually or in combination.Results: Using the new PERFORM classification system, patients with clinically confident bacterial diagnosis (“definite bacterial” category) had significantly higher levels of PCT, NGAL and resistin compared with those with a clinically confident viral diagnosis (“definite viral” category). Patients with diagnostic uncertainty had biomarker concentrations that varied across the spectrum. AUCs were higher for classification of “definite bacterial” vs. “definite viral” following the PERFORM algorithm than using the “SBI” vs. “non-SBI” classification; summary AUC for PCT was 0.77 (95% CI 0.72–0.82) vs. 0.70 (95% CI 0.65–0.75); for NGAL this was 0.80 (95% CI 0.69–0.91) vs. 0.70 (95% CI 0.58–0.81); for resistin this was 0.68 (95% CI 0.61–0.75) vs. 0.64 (0.58–0.69) The three biomarkers combined had summary AUC of 0.83 (0.77–0.89) for “definite bacterial” vs. “definite viral” infections and 0.71 (0.67–0.74) for “SBI” vs. “non-SBI.”Conclusion: Biomarkers of bacterial infection were strongly associated with the diagnostic categories using the PERFORM classification system in five independent cohorts. Our proposed algorithm provides a novel framework for phenotyping children with suspected or confirmed infection for future biomarker studies.